Primary endpoint of double-Blinded, Placebo-Controlled Interventional Study for Assessing Catheter Ablation Efficacy in Persistent Atrial Fibrillation was patient blinding; randomized in a 1:1 ratio
to receive either PVI±DCCV(PVI group) or DCCV+Placebo(DCCV group); looked at 20 patients in pilot for blinding, found RCT feasibility for blinded placebo-controlled trial & place had higher recurrence
Why this study? ‘there are no randomised, double-blinded clinical trials comparing catheter ablation to DC-cardioversion(DCCV) with medical therapy in patients with persistent atrial fibrillation(PersAF).’ ‘conducted a pilot study to evaluate the feasibility of conducting a definitive placebo-controlled trial.’
Dr. Paul, where do you find the energy, do you ever sleep?
A double blinded study that gives results that can improve patient’s lives! Great news for the growing number of people suffering from A-fib. Hopefully this will help people with post Covid syndrome. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959721/
Vaccine induced arrhythmia with Moderna seems to be a “rare” 😤 problem! https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862670/